Relay Therapeutics, Inc.
RLAY
$2.84
-$0.275-8.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.26% | 100.00% | -- | -- | 4,327.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.26% | 100.00% | -- | -- | 4,327.88% |
| Cost of Revenue | -10.43% | -12.78% | -5.98% | 4.30% | -0.51% |
| Gross Profit | 8.66% | 12.78% | -36.11% | -4.44% | 12.35% |
| SG&A Expenses | -5.35% | 0.76% | 6.84% | 0.09% | 1.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.45% | -9.85% | -3.61% | 3.52% | -0.20% |
| Operating Income | 7.95% | 9.85% | -28.88% | -3.63% | 9.77% |
| Income Before Tax | 5.31% | 8.97% | -34.03% | 6.39% | 13.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.31% | 8.97% | -34.03% | 6.39% | 13.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.31% | 8.97% | -34.03% | 6.39% | 13.64% |
| EBIT | 7.95% | 9.85% | -28.88% | -3.63% | 9.77% |
| EBITDA | 7.86% | 9.95% | -29.41% | -3.64% | 10.08% |
| EPS Basic | 26.78% | 32.14% | -16.83% | 14.23% | 19.93% |
| Normalized Basic EPS | 28.40% | 33.78% | -14.72% | 5.73% | 18.99% |
| EPS Diluted | 26.78% | 32.14% | -16.83% | 14.23% | 19.93% |
| Normalized Diluted EPS | 28.40% | 33.78% | -14.72% | 5.73% | 18.99% |
| Average Basic Shares Outstanding | 29.34% | 34.14% | 14.72% | 9.16% | 7.85% |
| Average Diluted Shares Outstanding | 29.34% | 34.14% | 14.72% | 9.16% | 7.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |